FIRE-3

NCT00433927 📎

Regimen

Experimental
Cetuximab + FOLFIRI
Control
Bevacizumab + FOLFIRI

Population

KRAS wild-type (later extended to RAS wild-type) metastatic CRC, 1L, previously untreated.

Key finding

1L mCRC KRAS-exon-2-wt: primary endpoint ORR cetuximab 62% vs bev 58% (p=0.183, NS); mOS 28.7 vs 25.0 mo (HR 0.77, 95% CI 0.62-0.96, p=0.017) favoring cetuximab; mPFS 10.0 vs 10.3 mo (HR 1.06, NS); depth of response significantly better with cetuximab; discordant PFS/OS pattern

Source: PMID 25088940

Timeline

    Guideline citations

    • NCCN Colon (p.58)
    • NCCN Rectal (p.75)